6.85 0.00 (0.00%)
After hours: 4:42PM EST
|Bid||6.32 x 1400|
|Ask||13.00 x 800|
|Day's Range||6.85 - 7.05|
|52 Week Range||5.65 - 11.10|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
PALO ALTO, Calif. , Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
PALO ALTO, Calif., Dec. 24, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018. "We are excited to be included in these indexes among some of the most innovative public companies in the U.S., as we look to broaden our investor base following our successful IPO in October," said John Borgeson, Kodiak's Chief Financial Officer.
-- Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population. -- Twelve weeks after a single dose, median vision improvement from baseline of almost two lines of vision (9 eye chart letters) and median improvement in retinal edema of 121 microns were achieved across all three dose levels tested. -- No dose-limiting toxicities, drug-related adverse events, or intraocular inflammation were observed through each patients' last visit at 12 weeks.
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
PALO ALTO, Calif. , Nov. 16, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
The Bay Area now has three startup accelerator programs ranted as the best in the nation, according to an annual ranking.
PALO ALTO, Calif. , Oct. 10, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9 , 2018 of its initial public offering of 9,000,000 shares of common stock at ...
PALO ALTO, Calif. , Oct. 3, 2018 /PRNewswire/ -- Kodiak Sciences Inc. ("Kodiak") today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Upwork Inc. (UPWK) will issue nearly 12.3 million shares between $10 and $12 Wednesday on the Nasdaq. Upwork’s online platform ...